Studies show that CXXC5 expression is markedly elevated in both NASH patients and mouse models, while KY19334, a small-molecule activator, enhances Wnt/β-catenin signaling to suppress hepatic lipogenic genes (PPAR-γ, CEBPA), reduce hepatic infiltration of F4/80+ and Cd11b+ Macrophages, and downregulate inflammatory and fibrogenic markers (TNF-α, Mcp1, α-SMA, Col1a1), exhibiting superior efficacy to current treatments (105). Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.